Overview S9005 Mifepristone in Meningioma Status: Completed Trial end date: 2012-11-01 Target enrollment: Participant gender: Summary To compare daily oral mifepristone vs placebo with respect to time to treatment failure in patients with unresectable meningioma. Phase: Phase 3 Details Lead Sponsor: Southwest Oncology GroupCollaborator: National Cancer Institute (NCI)Treatments: Mifepristone